
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics Inc. is poised for significant financial growth, with projections indicating risk-adjusted sales increasing to $171 million in 2026 and reaching a peak of $1.9 billion by 2031. The anticipated market penetration for relacorilant in ovarian cancer has increased to 25%, reflecting confidence in its clinical data, particularly following positive survival outcomes from the pivotal MIRASOL trial. Additionally, the strategic plan to launch relacorilant with a dedicated oncology sales force underscores the potential for commercial success, particularly as the company prepares for an upcoming pivotal decision on approval in July 2026.
Bears say
Corcept Therapeutics Inc is facing a negative outlook due to multiple factors reflected in its financial reports, primarily stemming from the Complete Response Letter (CRL) for its relacorilant drug, which is crucial for treating Cushing's syndrome, leading to significant drops in share price. The revisions in the financial model have resulted in a decrease of the 12-month price target to $90 per diluted share from $145, indicating diminished expectations for revenue growth as the delayed launch affects potential market entry timelines. Additionally, anticipated pricing pressure from payers may further negatively impact sales of Korlym, worsening the company’s financial projections and investor sentiment.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares